Pfizer, Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...
Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...
Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 focusing on vepdegestrant (ARV-471), an orally active selective oestrogen ...
IsomAb has also entered into a strategic collaboration with Pfizer Ignite to support preclinical development and IND-enabling studies for ISM-001, the company stated.
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
Now, despite playing no formal role in the battle between Pfizer and Starboard, Guggenheim has found itself in the crossfire of one of the messiest activist campaigns in recent Wall Street memory.
Pfizer will apply Triana Biomedicines’ target-first and proximity-first discovery platform to discover molecular glue degraders for unspecified “multiple” targets in oncology and several other ...
Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback